摘要
目的:探讨磺达肝癸钠及低分子肝素对非ST段高抬型急性状冠动脉综合征(NSTE-ACS)的治疗作用分析。方法:选取2019年10月~2020年12月在我院接受治疗的45例NSTE-ACS患者为研究对象,采用随机数字表法分为对照组22例以及观察组23例。对照组在常规干预治疗的基础上联合低分子肝素进行治疗,观察组在常规治疗的基础上联合磺达肝癸钠进行治疗。比较两组患者的临床疗效,临床症状缓解时间以及治疗3~7天后心血管等不良事件的发生率。结果:观察组和对照组患者的临床治疗有效率分别为95.65%、72.73%,组间比较差异具有统计学意义;观察组患者胸痛缓解时间以及ST段回降>50%的时间与对照组患者相比明显减少,差异具有统计学意义;治疗3~7天后,观察组患者新发心肌梗死以及新发心绞痛事件与对照组相比无统计学意义,但观察组患者出血事件的发生率相较对照组明显降低,差异有统计学意义;治疗干预后,观察组患者的PT、APTT与对照组相比明显升高,差异具有统计学意义。结论:对于NSTE-ACS患者,采用磺达肝癸钠治疗与低分子肝素治疗相比临床疗效更为显著、患者恢复时间明显减少,且出血事件的发生率也明显降低,安全性高。
Objective To investigate the therapeutic effect of fondaparinux sodium and low molecular weight heparin on non ST segment elevation acute coronary artery syndrome(NSTE-ACS).Methods Select 45 patients with non-ST-segment elevation acute coronary syndrome who were treated in our hospital from October 2019 to December 2020 as the research objects.According to the random number table method,the patients included in this study were divided into the control group(22 cases)and the observation group(23 cases).The control group was treated with low molecular weight heparin on the basis of routine intervention treatment,and the observation group was treated with fondaparinux sodium on the basis of routine treatment.The clinical efficacy,relief time of clinical symptoms and the incidence of cardiovascular adverse events after 3~7 days of treatment were compared between the two groups.Results The clinical effective rates of the observation group and the control group were 95.65%and 72.73%respectively,and the difference between the two groups was statistically significant;the relief time of chest pain and ST segment fall in the observation group were more than 50%of the time was significantly reduced compared with the control group,which was statistically significant;after 3~7 days of treatment,there was no significant difference in the incidence of new myocardial infarction and angina pectoris between the observation group and the control group,but the incidence of bleeding time in the observation group was significantly lower than that in the control group.After treatment,the PT,APTT in the observation group were significantly higher than those in the control group.Conclusion For patients with NSTE-ACS,compared with low molecular weight heparin,the clinical efficacy of fondaparinux sodium is more significant,the recovery time of patients is significantly reduced,the incidence of bleeding events is significantly reduced,and the safety is high.
作者
李志成
陈晓梅
马红红
Li Zhi-cheng;Chen Xiao-mei;Ma Hong-hong(Department of Cardiology,Xinhua Hospital of Huainan Xinhua Medical Group,Huainan 232052,China;Department of Nursing,Xinhua Hospital of Huainan Xinhua Medical Group,Huainan 232052,China;Department of Cardiology,The First Hospital of Yulin,Yulin 719000,China)
出处
《湖南师范大学学报（医学版）》
2021年第6期212-215,共4页
Journal of Hunan Normal University(Medical Sciences)
关键词
磺达肝癸钠
低分子肝素
非ST段高抬型急性冠状动脉综合征
fondaparinux sodium
low molecular weight heparin
non ST segment elevation acute coronary syndrome
